Tag: prospectus

UAB "Atsinaujinančios energetikos investicijos" (hereinafter, the “Company”) on 11 June 2025 has finished a public offering led by FMĮ “Orion securities” during which the Company has successfully distributed 32.274 MEUR Green Bonds first series and first tranche issue at 8.0% yield, under its EUR 100 million unsecured fixed-interest note programme. The base prospectus of the programme was approved by the Bank of Lithuania on 27 May 2025. This transaction marks a continuation of the implementation of a distinctive Green Bond Programme in the Baltic market. The proceeds from the note issuance will be used to refinance existing bonds (ISIN LT0000405938).

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

SEATTLE, June 12, 2025 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (Nasdaq: DDI) (“DoubleDown” or the “Company”) today announced the pricing of an underwritten secondary offering of 4,347,827 American Depositary Shares (the “ADSs”), each ADS representing 0.05 common share of the Company (“Common Shares”), at a public offering price of $8.50 per ADS by STIC Special Situation Diamond Limited (the “Selling Shareholder”). The Selling Shareholder has granted the underwriters a 30-day option to purchase up to 652,173 additional ADSs at the public offering price, less underwriting discounts and commissions. The offering consists entirely of the ADSs to be sold by the Selling Shareholder and will not change the number of Common Shares that are outstanding.

MAINZ and TÜBINGEN, Germany, June 12, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) and CureVac N.V. (Nasdaq: CVAC, “CureVac”) today announced that they have entered into a definitive Purchase Agreement pursuant to which BioNTech intends to acquire all of the shares of CureVac, a clinical-stage biotech company developing a novel class of transformative medicines in oncology and infectious diseases based on messenger ribonucleic acid (“mRNA”). The all-stock transaction will bring together two highly complementary companies based in Germany and will build on BioNTech’s proven track record and established position in the global mRNA industry.